New hope for Hard-to-Treat cancers: targeted combo therapy enters Mid-Stage trial
Disease control
Not yet recruiting
This study tests a new drug called IBI343 combined with other treatments for people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific marker (CLDN18.2). The goal is to see if the combination is safe and shrinks tumors. About 389 adults w…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 06, 2026 16:13 UTC